Update on TB therapies in development on November 1 teleconference

October 27, 2004

What: Teleconference to recap presentations given on TB therapies in development from the IUATLD conference in Paris and the ICAAC conference in Washington DC. Latest scientific studies and results will be shared; briefings from the Global Alliance for TB Drug Development (TB Alliance), leading pharmaceutical companies and academic laboratories will participate. There will be a Q&A session for journalists.

Why: New findings on the impact of TB and the critical need for the globally coordinated pipeline; response has been catalyzed and managed by the TB Alliance, a public private partnership created only four years ago to develop affordable, faster-acting drugs.

Tuberculosis infects one third of the world's population and is the oldest known human infection, but no new drugs have been introduced in over thirty years. There were few, if any, new candidates in development a decade ago. Standard TB treatment regimens for active carriers of the disease are resource-intensive and difficult to comply with due to their complexity and length (3-4 separate drugs for 6-9 months). Treatment of multi-drug resistant TB is difficult, costly, and far less effective, and a majority of MDR-TB strains are now resistant to three of the four first-line drugs. TB is the leading killer of AIDS patients, but simultaneous TB-HIV treatment is prevented by drug-drug interactions between some ARVs and old TB drugs.

The TB Alliance has brought together leading researchers, industry actors, and public health advocates to realize the first, most comprehensive TB drug pipeline since the 1960s.

Who:
  • Dr. Mel Spigelman, Global Alliance for TB Drug Development (TB Alliance)
  • Dr. Doris Rouse, RTI International
  • Dr. Thomas Keller, Novartis Institute for Tropical Diseases (NITD)
  • Dr. Carol Nacy, Sequella Inc.
  • Dr. Scott Franzblau, University of Illinois at Chicago

    How: US dial in + 800-223-9488 / International dial in +785-832-0326 Conference ID # 7TBDRUG

    When: Monday, November 1, 2004, 9.00 - 9.30 am EST time ( 2.00 - 2:30 pm GMT)

    Contact: Brenda Timm - 1-212-704-4593 - brenda.timm@edelman.com

    Editors Note: Please use the following link to review information referenced on the call http://www.tballiance.org/novartis.asp

    Edelman Public Relations

    Related Drugs Articles from Brightsurf:

    The danger of Z-drugs for dementia patients
    Strong sleeping pills known as 'Z-drugs' are linked with an increased risk of falls, fractures and stroke among people with dementia, according to new research.

    Wallflowers could lead to new drugs
    Plant-derived chemicals called cardenolides - like digitoxin - have long been used to treat heart disease, and have shown potential as cancer therapies.

    Bristol pioneers use of VR for designing new drugs
    Researchers at the University of Bristol are pioneering the use of virtual reality (VR) as a tool to design the next generation of drug treatments.

    Towards better anti-cancer drugs
    The Bayreuth biochemist Dr. Claus-D. Kuhn and his research team have deciphered how the important human oncogene CDK8 is activated in cells of healthy individuals.

    Separating drugs with MagLev
    The composition of suspicious powders that may contain illicit drugs can be analyzed using a quick and simple method called magneto-Archimedes levitation (MagLev), according to a new study published in the journal Angewandte Chemie.

    People are more likely to try drugs for the first time during the summer
    American teenagers and adults are more likely to try illegal or recreational drugs for the first time in the summer, a new study shows.

    Drugs used to enhance sexual experiences, especially in UK
    Combining drugs with sex is common regardless of gender or sexual orientation, reveals new research by UCL and the Global Drug Survey into global trends of substance-linked sex.

    Promising new drugs for old pathogen Mtb
    UConn researchers are targeting a metabolic pathway, the dihydrofolate reductase pathway, crucial for amino acid synthesis to treat TB infections.

    Can psychedelic drugs heal?
    Many people think of psychedelics as relics from the hippie generation or something taken by ravers and music festival-goers, but they may one day be used to treat disorders ranging from social anxiety to depression, according to research presented at the annual convention of the American Psychological Association.

    New uses for existing antiviral drugs
    Broad-spectrum antiviral drugs work against a range of viral diseases, but developing them can be costly and time consuming.

    Read More: Drugs News and Drugs Current Events
  • Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.